Inclusion Criteria

Inclusion Criteria

- Histologically confirmed, unresectable, locally advanced or metastatic gastric
cancer, including adenocarcinoma of the gastroesophageal junction (Phase II). For the
Phase Ib portion, any unresectable, locally advanced or metastatic solid tumor;

- ECOG PS of 0-1;

- Blood pressure must be well-controlled. Patients must have no history of hypertensive
crisis or hypertensive encephalopathy; Adequate end organ function

Exclusion Criteria

- Gastric cancer patients who have had a complete gastrectomy;

- Patients with known HER2 over-expressing advanced or metastatic gastric cancer;

- Previously received E7050, its chemical derivatives, anti-cMet, anti-angiogenic
therapy, (prior anti-angiogenic therapy is permitted in Phase Ib only).

- For Phase Ib prior systemic therapy is allowed as long as PS and end organ function
meet entry criteria;

- For Phase II no prior palliative chemotherapy is permitted. Adjuvant/neoadjuvant
chemotherapy is permitted if >12 months have elapsed between the end of
adjuvant/neoadjuvant therapy and first recurrence;

- Known central nervous system lesions, except for asymptomatic non-progressing,
treated brain metastases. Treatment for brain mets, but have been completed at least
4 weeks prior to Day 1

- Palliative radiotherapy is not permitted throughout the study period. Prior
palliative radiotherapy within 30 days prior to commencing study treatment;

- Clinically significant hemoptysis;

- Patients with known dihydropyrimidine dehydrogenase deficiency;

- Patients with clinically significant hearing loss that may be further diminished by
treatment with cisplatin plus capecitabine (significance of hearing loss to be
determined by the Investigator;

- Serious non-healing wound, ulcer, or active bone fracture;

- Major surgical procedure, open biopsy, or significant traumatic injury within the 21
days prior to commencing study treatment;

- Clinically significant gastrointestinal bleeding within 6 months prior to first dose.